‘Suicide’ Gene Therapy for Prostate Cancer Shows Promise

‘Suicide’ Gene Therapy for Prostate Cancer Shows Promise
A phase II trial evaluating combination of radiotherapy and an experimental treatment driving tumor cells to self-destruct achieved promising results in cancer regression and presented no indication of tumor recurrence. The results, entitled “Long-term outcome of a phase II trial using immunomodulatory in situ gene therapy in combination with intensity-modulated radiotherapy with or without hormonal therapy in the treatment of prostate cancer,” were published in the Journal of Radiation Oncology. The “suicide gene therapy” strategy consists of introducing a herpes virus gene that produces the enzyme thymidine kinase (TK) directly into the tumor cells, using adenovirus as a delivery method. Once the gene is delivered and expresses TK, anti-herpes drug valacyclovir is given to the patients, leading TK-producing cells to self-destruct when in contact with the drug, further alerting the immune system to the presence of cancer cells. Senior author Dr E. Brian Butler, M.D,  commented in a press release, “We have created a vaccine with the patient's own cancer cells, a treatment that complements, and may even enhance, what we can achieve with traditional radiation and hormonal therapies." Researchers enrolled 66 patients in the phase II trial from 1999 to 2003, and divided them into two groups of 33 patients: group arm A, consisting of patients with cancer confined to the prostate (Gleason score <7, pretreatment PSA <10) who received radiotherapy and the experimental gene therapy twice during the study; and the group arm B,
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *